Sanofi pays Synthekine $40M to join preclinical push against vexing inflammatory target

[cafead]

via Sanofi is paying $40 million to add another cytokine—IL-10—to its hit list. The upfront fee has secured the French drugmaker the chance to work with Synthekine to overcome long-standing barriers to the use of the cytokine in the treatment of inflammatory diseases.

article source